Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation
Faron again published positive results of the BEXMAB study that focuses on blood cancers. The company seems to have preliminary efficacy proof already in the phase I/II study, which we believe supports the probabilities of the study path being successful. With the positive estimate changes justified by the results we feel that the valuation picture of the share is slightly more neutral, but still not sufficiently attractive in terms of the risk/return ratio.
Faron Pharmaceuticals
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. Faron is based in Turku, Finland.
Read more on company pageKey Estimate Figures17.04.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 |
growth-% | |||
EBIT (adj.) | -27.4 | -15.8 | -3.1 |
EBIT-% (adj.) | -685,650.00 % | -394,522.50 % | -76,864.00 % |
EPS (adj.) | -0.48 | -0.25 | -0.05 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |